ClinicalTrials.gg
Active, not recruitingNCT05953337Updated Mar 4, 2026

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

An interventional study of EYE90 Microspheres Treatment in Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable and Liver Cancer, sponsored by ABK Biomedical. Active, not recruiting at 22 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by ABK Biomedical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
164th of 775
120 · median 36
Started
2023
with 45 others
No phase
124 of 926
26 open now
Primary completion
2027-02
later than 88 of 244 live
Registered
806th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 164th largest by planned enrollment of the 775 interventional ones that give a count, is one of 46 that started in 2023, is one of 124 with no phase, reaches primary completion later than 88 of the 244 other live ones, and was the 806th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Non-resectable
  • Liver Cancer

Keywords

  • Hepatocellular Carcinoma
  • Liver Cancer
  • Liver Diseases
  • Internal radiation brachytherapy
  • Radioembolization
  • Y90
  • Yttrium-90
  • Eye90 microspheres
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a confirmed diagnosis of HCC by imaging confirmation with Liver Imaging Reporting and Data System (LIRADS) category 5 or confirmation of HCC via .
  • No extra hepatic disease.
  • Up to 3 lesions with at least one lesion ≥ 2 cm in diameter (long axis) measurable by computed tomography (CT), CBCT, or MRI. At least one lesion must be identified as a target lesion as defined by .
  • Maximal single lesion size of ≤ 8 cm and sum of the maximal tumor dimensions of ≤ 12 cm with the entire tumor burden expected to be treatable within the perfused volume.
  • Intent to treat all lesions within a single session.
  • Hypervascular on CBCT, CT, or MRI.
  • Evidence that > 33% of the total liver volume is disease-free and will be spared Eye90 treatment.
  • of ≥ 6 months.
  • ≥ 18 years old at the time of

Exclusion criteria

Exclusion Criteria:

  • count \<50,000/microliter or prothrombin (PT) activity > 50% normal.
  • ≤ 8.5 g/dL (subjects that are non-responders to transfusion or medical management must be excluded).
  • > 1.7 (if anticoagulated, reversal must be achieved prior to any angiographic procedures).
  • > 5x upper limit.
  • AST > 5x upper limit.
  • ≥ 2.0 mg/dL.
  • ≤ 50 mL/min/BSA.
  • Macrovascular invasion.
  • Incompetent biliary duct system, prior biliary intervention, or a compromised Ampulla of Vater.
  • Estimated lung dose > 30 Gy as calculated using the lung shunt fraction and partition model.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    EYE90 Microspheres Treatment

    Radioembolization with Eye90 Microspheres

    Device: EYE90 Microspheres Treatment

Interventions

  • DeviceEYE90 Microspheres Treatment

    Y90 glass microspheres

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    The percentage of subjects with ORR using local mRECIST, as assessed by independent panel review.

    Time frame: 6 months

  2. Duration of response (DoR)

    DoR is defined as response ≥ 6 months for ≥ 60% of responders first occurrence of CR or PR

    Time frame: 6 months

  3. Incidence of adverse events (AEs)

    Incidence of AEs, grouped by System Organ Class (SOC) and Preferred Term (PT), relatedness to study treatment/procedure, and severity.

    Time frame: 12 months

  4. Incidence of serious adverse events (SAEs)

    Incidence of SAEs, grouped by SOC and PT, relatedness to study treatment/procedure, and severity.

    Time frame: 12 months

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

Of 385 interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Jul 20, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953337
Lead sponsor
ABK Biomedical
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Sep 21, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Andrew Kennedy, MD
principal investigator · Director, Radiation Oncology Research at Sarah Cannon
Ammar Sarwar, MD
principal investigator · Director of Radiation Oncology Research, Beth Israel Deaconess Medical Center
Aravind Arepally, MD
study director · ABK Biomedical, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion